PATHOGENESIS OF AORTIC STENOSIS IN HYPERTENSIVE PATIENTS
https://doi.org/10.18705/1607-419X-2013-19-6-495-501
Abstract
Objective. To assess osteoprotegerin (OPG) and soluble ligand receptor activator of transcription factor kappa-B (RANKL) levels in patients with aortic stenosis and systemic hypertension.
Design and methods. Sixty-one patients with aortic valve stenosis (AVS) [31 patients with bicuspid aortic valve (BAV) and 30 patients with tricuspid aortic valve (TAV)] were examined. Thirty-two patients without heart diseases formed the control group. Serum levels of C-reactive protein, ОPG, sRANKL and lipid profile were assessed in all patients.
Results. Elevated blood pressure (BP) was found in 93 % patients with TAV and in 71 % patients with BAV. Serum concentration of OPG was increased in patients with TAV and BAV vs control group. OPG concentration was negatively correlated with BP level only in patients with TAV. sRANKL level was increased only in patients with BAV. At the same time sRANKL level positively correlated with BP in patients with TAV.
Conclusion. Systemic hypertension is the key risk factor for OPG/RANKL/RANK system activation in patients without congenital heart disease.
About the Authors
O. B. Irtyuga
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
Corresponding author: Federal Almazov Medical Research Centre, 2 Akkuratov st., St Petersburg, Russia, 197341. Е-mail: olgir@yandex.ru (Olga B. Irtyuga, MD, PhD, the Leading Researcher at the Research Laboratory for Cardiomyopathies at the Federal Almazov Medical Research Centre).
E. V. Zhiduleva
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
E. E. Kazakova
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
O. M. Moiseeva
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
References
1. Iung B., Vahanian A. Valvular heart disease in elderly people // Lancet. — 2006. — Vol. 368, № 9540. — P. 969–971.
2. Rajamannan N.M. Update on the pathophysiology of aortic stenosis // Eur. Heart J. — 2008. — Vol. 10, Suppl. E. — P. E4–E10.
3. Шабалин А.В., Чибисова Е.А., Верещагина Г.Н. Сочетание кальцинированного стеноза аортального клапана дегенеративного генеза и артериальной гипертензии // Бюлл. СО РАМН. — 2008. — T. 3, № 131. — С. 5–8. // Shabalin A.V., Chibisova E.A., Verechagin G.N. The combination of degenerative aortic valve stenosis and arterial hypertension // Bulletin of Siberian Division of Russian Academy of Medical Science. — 2008. — Vol. 3, № 131. — P. 5–8 [Russian].
4. Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F. et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 5. — P. 554–561.
5. Chan K.L., Teo K., Dumesnil J.G., Ni A., Tam J. et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial // Circulation. — 2010. — Vol. 121, № 2. — P. 306–314.
6. Messika-Zeitoun D., Bielak L.F., Peyser P.A. et al. Aortic valve calcification: determinants and progression in the population // Arterioscler. Vasc. Thromb. Biol. — 2007. — Vol. 27, № 3. — P. 642–648.
7. Natorska J., Marek G., Hlawaty M. et al. Evidence for tissue factor expression in aortic valves in patients with aortic stenosis // Pol. Arch. Med. Wewn. — 2009. — Vol. 119, № 10. — P. 636–643.
8. Caira F.C., Stock S.R., Gleason T.G. et al. Human de- Caira F.C., Stock S.R., Gleason T.G. et al. Human degenerative valve diseaseis associated with up-regulation of lowdensity lipoprotein receptor-related protein 5 receptor-mediated bone formation // J. Am. Coll. Cardiol. — 2006. — Vol. 47, № 8. — P. 1707–1712.
9. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases // J. Am. Med. Assoc. — 2004. — Vol. 292, № 4. — P. 490–495.
10. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin // Circ. Res. — 2004. — Vol. 95, № 11. — P. 1046–1057.
11. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification // Genes. Dev. — 1998. — Vol. 12, № 9. — P. 1260–1268.
12. Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G. et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in Ldrl mice // Circulation. — 2008. — Vol. 117, № 3. — P. 411–420.
13. Baumgartner H., Hung J., Bermejo J. et al. Echocardio- Baumgartner H., Hung J., Bermejo J. et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice // J. Am. Soc. Echocardiogr. — 2009. — Vol. 22, № 1. — P. 1–23.
14. Ward C. Clinical significance of the bicuspid aortic valve // Heart. — 2000. — Vol. 83, № 1. — P. 81–85.
15. David R.H., Michael J.M., Kaul S. et al. ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement // J. Am. Coll. Cardiol. — 2012. — Vol. 59, № 13. — P. 1200–1254.
16. Hjortnaes J., Aikawa E. Calcific aortic valve disease. — 2011. ISBN: 9535111504 9789535111504. — P. 133–162.
17. Blazquez-Medela A., Garcia-Ortiz L. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes // Eur. J. Clin. Invest. — 2012. — Vol. 42, № 5. — P. 548–556.
18. Lieb W., Gona Ph., Larson M.G. Biomarkers of the osteoprotegerin pathway. Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality // Arterioscler. Thromb. Vasc. Biol. — 2010. — Vol. 30, № 9. — P. 1849–1854.
19. Schoppet M., Schaefer J.R., Hofbauer L.C. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men // Circulation. — 2003. — Vol. 107, № 11. — P. e76.
20. Lieb W., Gona P., Larson M.G. Biomarkers of the osteoprotegerin pathway clinical correlates, subclinical disease, incident cardiovascular disease, and mortality // Arterioscler. Thromb. Vasc. Biol. — 2010. — Vol. 30, № 9. — P. 1849–1854.
21. Orlowska-Baranowska E. Hypertension in aortic stenosis: More questions than answers // Cardiol. J. — 2013. — Vol. 20, № 1. — Р. 4.
22. Valhanian A., Alfieri O., Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force ofthe Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. J. Cardiothorac. Surg. — 2012. — Vol. 42, № 4. — P. S1–S44.
23. Kaden J.J., Bickelhaupt S., Grobholz R. et al. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification // J. Mol. Cell. Cardiol. — 2004. — Vol. 36, № 1. — P. 57–66.
24. Weiss R.M., Lund D.D., Chu Y. et al. Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice // PLoS One. — 2013. — Vol. 8, № 6. — Р. e65201.
25. Akat K., Kaden J.J., Schmitz F. et al. Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function // Am. J. Cardiol. — 2010. — Vol. 105, № 6. — P. 862–864.
26. Bruneau B.G. The developmental genetics of congenital heart disease // Nature. — 2008. — Vol. 451, № 7181. — P. 943–948.
27. Nadir M.A., Wei L., Elder D.H. et al. Impact of reninangiotensin system blockade therapy on outcome in aortic stenosis // J. Am. Coll. Cardiol. — 2011. — Vol. 58, № 6. — P. 570–576.
28. Гончарова Н.С., Моисеева О.М., Алешина Г.М., Шляхто Е.В.Типы гипертрофии миокарда левого желудочка и система матриксных металлопротеиназ у пациентов с клапанными пороками // Артериальная гипертензия. — 2007. — Т. 13, № 4. — С. 287–291. // Goncharova N.S., Moiseeva O.M., Aleshina G.M., Shlyakhto E.V. Type of left ventricular hypertrophy and matrix metalloproteinase in patient with valvular disease // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2007. — Vol. 13, № 4. — Р. 287–291 [Russian].
Review
For citations:
Irtyuga O.B., Zhiduleva E.V., Kazakova E.E., Moiseeva O.M. PATHOGENESIS OF AORTIC STENOSIS IN HYPERTENSIVE PATIENTS. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(6):495-501. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-6-495-501
Views:
1533
Email this article 